Selank has limited human research, mainly from regional anxiety studies, but the evidence base is small and not widely replicated. Modern long-term safety and general cognitive-enhancement claims remain uncertain.
Still uncertain: Reliable modern anxiety-treatment benefit, cognitive enhancement in healthy people, long-term safety or a validated compounded regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Synthetic tuftsin-derived heptapeptide
Entity type
Peptide
Research focus
Anxiety/stress and neurocognitive research
Human evidence
Older regional comparative studies report anxiolytic signals in generalized anxiety and related disorders, but modern large placebo-controlled independent replication is sparse.
Regulatory status
Not FDA/EMA-approved; FDA highlights limited safety information for compounded use.
Main limitations
Modern first-line anxiolytic efficacy, healthy-person cognitive enhancement, long-term safety or a validated compounded regimen.
Safety
International safety dataset is limited; FDA notes insufficient safety information for compounded Selank.
Evidence reviewed
2026-09-18
i
Older regional comparative studies report anxiolytic signals in generalized anxiety and related disorders, but modern large placebo-controlled independent replication is sparse.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
International safety dataset is limited; FDA notes insufficient safety information for compounded Selank.
FDA says important safety information for compounded Selank acetate is lacking; aggregation, impurities and immunogenicity are relevant formulation concerns.
Technical details
Mechanism / biologyProposed modulation of GABAergic and neuroimmune signalling; exact clinical mechanism remains uncertain.
Route / formulation boundaryRegional intranasal studies do not establish universal product equivalence or long-term safety.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified human study regimen added with conference-abstract caveat. A 20-patient GAD study reported Selank 2700 micrograms/day intranasally. This is a study exposure from a conference abstract, not an approved or validated general-use regimen.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
4outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
